BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

INA Solar is building a 3 GW solar cell manufacturing line in central India, as part of a broader expansion that includes 4 GW of module capacity and aluminium frame production. It aims to begin ...

Lauren Ingrid Flanigan, the Australian woman accused of fatally stabbing her 3-year-old daughter on May 26, has died after being found unresponsive in her jail cell on May 31. An investigation is ...

The therapeutic landscape of small cell lung cancer (SCLC) is undergoing a paradigm shift with the emergence of delta-like ligand-3 (DLL3)–directed therapies, particularly tarlatamab, a first-in-class ...

A phase 3 trial of the androgen receptor ligand-directed degrader, BMS-986365, versus investigator’s choice in patients with metastatic castration-resistant prostate cancer (CA071-1000 - rechARge).

The facility to manufacture cell therapies for cancer research is part of the company's push to invest $3.5B in its U.S. operations by the end of 2026.

Following a successful Type B end-of-phase 2 meeting, the FDA has approved the start of a phase 3 trial of linperlisib in peripheral T-cell lymphoma.

ACLU urges 2nd Circuit to rethink no-warrant cellphone searches at US border The civil rights group likened searching personal digital devices to searching a home — or the contents of someone's mind.

At last week’s American Chemical Society Spring meeting, Bristol Myers Squibb Co. discussed the development of a potent, orally bioavailable and highly selective cereblon (CRBN)-mediated ...

The demand for compact battery management systems (BMS) in applications such as two-wheelers and uninterruptible power supplies has driven the development of battery management integrated circuits ...